PDCD1 and neoplasm: To gain potential mechanistic insight for the observed treatment resistance over time, AT3OVA tumour-bearing mice were treated with vehicle for 15 days or the combination of olaparib, AZD1775 and anti-PD-1 for 15, 30, 45 and 60 days.